<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FARXIGA- dapagliflozin propanediolÂ tablet, film coatedÂ </strong><br>E.R. Squibb &amp; Sons, L.L.C.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use FARXIGA safely and effectively.  See full prescribing information for FARXIGA.<br><br>FARXIGA (dapagliflozin) tablets, for oral use<br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. <a href="#ID_232d9b41-bf82-43c9-bb68-b5083e5abd65">(1)</a> </p>
<p class="Highlighta"><br>Limitation of use: </p>
<dl>
<dt>â€¢</dt>
<dd>Not for treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <a href="#ID_f943439c-7165-41c2-8cdd-1553322c254c">(1.1)</a>
</dd>
</dl>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>The recommended starting dose is 5 mg once daily, taken in the morning, with or without food. <a href="#ID_121e6f93-3ced-4638-bf9e-eba49459594b">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Dose can be increased to 10 mg once daily in patients tolerating FARXIGA who require additional glycemic control. <a href="#ID_121e6f93-3ced-4638-bf9e-eba49459594b">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>Assess renal function before initiating FARXIGA. Do not initiate FARXIGA if eGFR is below 60 mL/min/1.73 m<span class="Sup">2</span>. <a href="#ID_8dbfb145-ce00-4958-be5d-b50f7f9faf68">(2.2)</a>
</dd>
<dt>â€¢</dt>
<dd>Discontinue FARXIGA if eGFR <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> persistently below 60 mL/min/1.73 m<span class="Sup">2</span>. <a href="#ID_8dbfb145-ce00-4958-be5d-b50f7f9faf68">(2.2)</a>
</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Tablets: 5 mg and 10 mg <a href="#ID_ca949897-b6c9-4080-abe9-8c486d17a149">(3)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to FARXIGA. <a href="#ID_81425830-0e2c-411d-9e4c-5c09c6eca667">(4)</a>
</dd>
<dt>â€¢</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or dialysis. <a href="#ID_81425830-0e2c-411d-9e4c-5c09c6eca667">(4)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span> Before initiating FARXIGA, assess volume status and correct <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> in the elderly, in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. <a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">(5.1</a>, <a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">6.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Impairment in renal function:</span> Monitor renal function during therapy. <a href="#ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393">(5.2)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>:</span> In patients taking insulin or an insulin secretagogue with FARXIGA, consider a lower dose of insulin or the insulin secretagogue to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. <a href="#ID_e900c648-db48-4beb-9b59-f996eba00d94">(5.3)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</span> Monitor and treat if indicated. <a href="#ID_3745c009-b8d6-43ba-abf7-7dadfec65295">(5.4)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Increased LDL-C:</span> Monitor and treat per standard of care. <a href="#ID_714c264a-a537-48ce-9641-a417f42165b4">(5.5)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span>: </span>An imbalance in <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancers</span> was observed in clinical trials. FARXIGA should not be used in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> and should be used with caution in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. <a href="#ID_dad44c90-ecc7-4931-a527-1f3a46895fda">(5.6)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Macrovascular outcomes:</span> There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with FARXIGA or any other antidiabetic drug. <a href="#ID_6b407000-6f01-4d62-8d02-18906c116cd4">(5.7)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>The most common adverse reactions associated with FARXIGA (5% or greater incidence) were female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. <a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">(6.1)</a>
</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Pregnancy:</span> There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. <a href="#ID_631c78c9-089e-4252-9ff5-deed29b21c97">(8.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Nursing Mothers:</span> Discontinue FARXIGA or discontinue nursing. <a href="#ID_e20f5b2a-a410-410f-ad4d-10bbb72bde0d">(8.3)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Geriatrics:</span> Higher incidence of adverse reactions related to reduced intravascular volume. <a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">(5.1</a>, <a href="#ID_4a4f094a-f6b5-4b8e-8e00-34e712bc2c4e">8.5)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Higher incidence of adverse reactions related to reduced intravascular volume and renal function. <a href="#ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393">(5.2</a>, <a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">6.1</a>, <a href="#ID_40fa6b7d-6302-4cb3-9914-8fdd42b33f34">8.6)</a>
</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>â†”</div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
</div></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Impairment in Renal Function</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Increases in Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C)</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Positive Urine Glucose Test</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Interference with 1,5-anhydroglucitol (1,5-AG) Assay</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Overview of Clinical Studies of FARXIGA for Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Monotherapy</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Initial Combination Therapy with Metformin</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Add-On to Metformin</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Active Glipizide-Controlled Study Add-On to Metformin</a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Add-On Combination Therapy with Other Antidiabetic Agents</a></h2>
<h2><a href="#section-13.7" class="toc">14.7 Use in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_232d9b41-bf82-43c9-bb68-b5083e5abd65"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">FARXIGA (dapagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus [see <span class="Italics"><a href="#ID_76c6053f-7492-4388-8eb8-2b250575b5f0">Clinical Studies (14)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f943439c-7165-41c2-8cdd-1553322c254c"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Limitation of Use</h2>
<p class="First">FARXIGA is not recommended for patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_27237d11-01fd-4875-bcbc-c44d87117bf7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_121e6f93-3ced-4638-bf9e-eba49459594b"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">The recommended starting dose of FARXIGA is 5 mg once daily, taken in the morning, with or without food. In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, correcting this condition prior to initiation of FARXIGA is recommended [see <span class="Italics"><a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">Warnings and Precautions (5.1)</a></span>, <span class="Italics"><a href="#ID_4a4f094a-f6b5-4b8e-8e00-34e712bc2c4e">Use in Specific Populations (8.5</a>, <a href="#ID_40fa6b7d-6302-4cb3-9914-8fdd42b33f34">8.6)</a></span>, and <span class="Italics"><a href="#ID_41e47a06-53e3-4414-9d7d-6afc2177b899">Patient Counseling Information (17)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8dbfb145-ce00-4958-be5d-b50f7f9faf68"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Assessment of renal function is recommended prior to initiation of FARXIGA therapy and periodically thereafter.</p>
<p>FARXIGA should not be initiated in patients with an eGFR less than 60 mL/min/1.73 m<span class="Sup">2</span>.</p>
<p>No dose adjustment is needed in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR of 60 mL/min/1.73Â m<span class="Sup">2</span> or greater).</p>
<p>FARXIGA should be discontinued when eGFR is persistently less than 60 mL/min/1.73 m<span class="Sup">2</span> [see <span class="Italics"><a href="#ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393">Warnings and Precautions (5.2)</a></span> and <span class="Italics"><a href="#ID_40fa6b7d-6302-4cb3-9914-8fdd42b33f34">Use in Specific Populations (8.6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_ca949897-b6c9-4080-abe9-8c486d17a149"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>â€¢</dt>
<dd>FARXIGA 5 mg tablets are yellow, biconvex, round, film-coated tablets with â€œ5â€? engraved on one side and â€œ1427â€? engraved on the other side.</dd>
<dt>â€¢</dt>
<dd>FARXIGA 10 mg tablets are yellow, biconvex, diamond-shaped, film-coated tablets with â€œ10â€? engraved on one side and â€œ1428â€? engraved on the other side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_81425830-0e2c-411d-9e4c-5c09c6eca667"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>â€¢</dt>
<dd>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to FARXIGA [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>].</dd>
<dt>â€¢</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD), or patients on dialysis [see <span class="Italics"><a href="#ID_40fa6b7d-6302-4cb3-9914-8fdd42b33f34">Use in Specific Populations (8.6)</a></span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_0b478abb-ea6a-49ac-b062-7b7d98f45890"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8cb7c5eb-a657-4079-b403-83d52999887d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">FARXIGA causes intravascular volume contraction. Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> can occur after initiating FARXIGA [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>] particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (eGFR less than 60 mL/min/1.73 m<span class="Sup">2</span>), elderly patients, or patients on loop diuretics. Before initiating FARXIGA in patients with one or more of these characteristics, volume status should be assessed and corrected. Monitor for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after initiating therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Impairment in Renal Function</h2>
<p class="First">FARXIGA increases serum creatinine and decreases eGFR. Elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may be more susceptible to these changes. Adverse reactions related to renal function can occur after initiating FARXIGA [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>]. Renal function should be evaluated prior to initiation of FARXIGA and monitored periodically thereafter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e900c648-db48-4beb-9b59-f996eba00d94"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues</h2>
<p class="First">Insulin and insulin secretagogues are known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. FARXIGA can increase the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when combined with insulin or an insulin secretagogue [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>]. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when these agents are used in combination with FARXIGA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3745c009-b8d6-43ba-abf7-7dadfec65295"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">FARXIGA increases the risk of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Patients with a history of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more likely to develop genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>]. Monitor and treat appropriately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_714c264a-a537-48ce-9641-a417f42165b4"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Increases in Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDL-C)</h2>
<p class="First">Increases in LDLâ€‘C occur with FARXIGA [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>]. Monitor LDLâ€‘C and treat per standard of care after initiating FARXIGA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dad44c90-ecc7-4931-a527-1f3a46895fda"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span></h2>
<p class="First">Across 22 clinical studies, newly diagnosed cases of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> were reported in 10/6045 patients (0.17%) treated with FARXIGA and 1/3512 patient (0.03%) treated with placebo/comparator. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were 4 cases with FARXIGA and no cases with placebo/comparator. <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder cancer</span> risk factors and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (a potential indicator of pre-existing tumors) were balanced between treatment arms at baseline. There were too few cases to determine whether the emergence of these events is related to FARXIGA.</p>
<p>There are insufficient data to determine whether FARXIGA has an effect on pre-existing bladder tumors. Consequently, FARXIGA should not be used in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. In patients with prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, the benefits of glycemic control versus unknown risks for cancer recurrence with FARXIGA should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6b407000-6f01-4d62-8d02-18906c116cd4"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with FARXIGA or any other antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_67ac4aa3-79dc-4520-adf1-722248ed9e9d"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following important adverse reactions are described below and elsewhere in the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> [see <span class="Italics"><a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">Warnings and PrecautionsÂ (5.1)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Impairment in Renal Function [see <span class="Italics"><a href="#ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393">Warnings and PrecautionsÂ (5.2)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> with Concomitant Use with Insulin and Insulin Secretagogues [see <span class="Italics"><a href="#ID_e900c648-db48-4beb-9b59-f996eba00d94">Warnings and Precautions (5.3)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> [see <span class="Italics"><a href="#ID_3745c009-b8d6-43ba-abf7-7dadfec65295">Warnings and PrecautionsÂ (5.4)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Increases in Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (LDLâ€‘C) [see <span class="Italics"><a href="#ID_714c264a-a537-48ce-9641-a417f42165b4">Warnings and PrecautionsÂ (5.5)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span> [see <span class="Italics"><a href="#ID_dad44c90-ecc7-4931-a527-1f3a46895fda">Warnings and Precautions (5.6)</a></span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7a467fdb-90bc-4a6e-a42b-9b81e45e655d"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Pool of 12 Placebo-Controlled Studies for FARXIGA 5 and 10 mg</span></h3>
<p class="First">The data in Table 1 is derived from 12 placebo-controlled studies ranging from 12 to 24 weeks. In 4 studies FARXIGA was used as monotherapy, and in 8 studies FARXIGA was used as add-on to background antidiabetic therapy or as combination therapy with metformin [see <span class="Italics"><a href="#ID_76c6053f-7492-4388-8eb8-2b250575b5f0">Clinical Studies (14)</a></span>]<span class="Italics">.</span></p>
<p>These data reflect exposure of 2338 patients to FARXIGA with a mean exposure duration of 21 weeks. Patients received placebo (N=1393), FARXIGA 5 mg (N=1145), or FARXIGA 10 mg (N=1193) once daily. The mean age of the population was 55 years and 2% were older than 75 years of age. Fifty percent (50%) of the population were male; 81% were White, 14% were Asian, and 3% were Black or African American. At baseline, the population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for an average of 6 years, had a mean hemoglobin A1c (HbA1c) of 8.3%, and 21% had established microvascular complications of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Baseline renal function was normal or mildly impaired in 92% of patients and moderately impaired in 8% of patients (mean eGFR 86 mL/min/1.73 m<span class="Sup">2</span>). </p>
<p>Table 1 shows common adverse reactions associated with the use of FARXIGA. These adverse reactions were not present at baseline, occurred more commonly on FARXIGA than on placebo, and occurred in at least 2% of patients treated with either FARXIGA 5 mg or FARXIGA 10 mg.</p>
<a name="_RefID0EKSAE"></a><table cellpadding="5.75pt" width="100%">
<caption><span>Table 1: Adverse Reactions in Placebo-Controlled Studies Reported in â‰¥2% of Patients Treated with FARXIGA</span></caption>
<col width="42%">
<col width="12%">
<col width="22%">
<col width="24%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">% of Patients</span></th>
</tr>
<tr>
<th class="Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><span class="Bold">Pool of 12 Placebo-Controlled Studies</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">N=1393</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA 5 mg</span><br><span class="Bold">N=1145</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA 10 mg</span><br><span class="Bold">N=1193</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include the following adverse reactions, listed in order of frequency reported for females: vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>, <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vulvovaginal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span>, <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">genital candidiasis</span>, fungal <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span>, <span class="product-label-link" type="condition" conceptid="4269221" conceptname="Vulvitis">vulvitis</span>, genitourinary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4056330" conceptname="Furuncle of vulva">vulval abscess</span>, and <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">vaginitis bacterial</span>. (N for females: Placebo=677, FARXIGA 5 mg=581, FARXIGA 10 mg=598).<br><span class="Sup">â€ </span>Â Â <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> include the following adverse reactions, listed in order of frequency reported: <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="Emphasis">Escherichia</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, genitourinary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="441615" conceptname="Trigonitis">trigonitis</span>, <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>, <span class="product-label-link" type="condition" conceptid="192964" conceptname="Infectious disorder of kidney">kidney infection</span>, and <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>.<br><span class="Sup">â€¡</span>Â Â Increased urination includes the following adverse reactions, listed in order of frequency reported: <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, and urine output increased. <br><span class="Sup">Â§</span>Â Â Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include the following adverse reactions, listed in order of frequency reported for males: <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>, fungal <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span>, <span class="product-label-link" type="condition" conceptid="4199600" conceptname="Candidal balanitis">balanitis candida</span>, <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">genital candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4207302" conceptname="Male genital infection">genital infection male</span>, <span class="product-label-link" type="condition" conceptid="4205814" conceptname="Infection of penis">penile infection</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span> infective, <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span>, posthitis. (N for males: Placebo=716, FARXIGA 5Â mg=564, FARXIGA 10 mg=595).</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Female genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>*</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span><span class="Sup">â€ </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Increased urination<span class="Sup">â€¡</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Male genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span><span class="Sup">Â§</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span> with urination </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.7</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e277cbe-300d-46bf-961e-fc537d77da34"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Pool of 13 Placebo-Controlled Studies for FARXIGA 10 mg</span></h3>
<p class="First">The safety and tolerability of FARXIGA 10 mg was also evaluated in a larger placebo-controlled study pool. This pool combined 13 placebo-controlled studies, including 3 monotherapy studies, 9 add-on to background antidiabetic therapy studies, and an initial combination with metformin study. Across these 13 studies, 2360 patients were treated once daily with FARXIGA 10 mg for a mean duration of exposure of 22 weeks. The mean age of the population was 59 years and 4% were older than 75 years. Fifty-eight percent (58%) of the population were male; 84% were White, 9% were Asian, and 3% were Black or African American. At baseline, the population had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> for an average of 9 years, had a mean HbA1c of 8.2%, and 30% had established microvascular disease. Baseline renal function was normal or mildly impaired in 88% of patients and moderately impaired in 11% of patients (mean eGFR 82 mL/min/1.73 m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d9c3a16b-67b4-446c-bed7-ad6437648783"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span></span></h3>
<p class="First">FARXIGA causes an osmotic <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, which may lead to reductions in intravascular volume. Adverse reactions related to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> (including reports of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) are shown in Table 2 for the 12-study and 13-study, short-term, placebo-controlled pools [see <span class="Italics"><a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">Warnings and Precautions (5.1)</a></span>].</p>
<a name="_RefID0ET3AE"></a><table width="100%">
<caption><span>Table 2: Adverse Reactions of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume Depletion</span>* in Clinical Studies with FARXIGA</span></caption>
<col width="45%">
<col width="9%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="13%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Pool of 12 Placebo-Controlled</span><br><span class="Bold">Studies</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Pool of 13 Placebo-Controlled</span><br><span class="Bold">Studies</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">5 mg</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">10 mg</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">10 mg</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">*Â Â <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Volume depletion</span> includes reports of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Overall population N (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">N=1393</p>
<p>5 (0.4%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">N=1145</p>
<p>7 (0.6%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">N=1193</p>
<p>9 (0.8%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">N=2295</p>
<p>17 (0.7%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">N=2360</p>
<p>27 (1.1%)</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6"><p class="First"><span class="Bold">Patient Subgroup n (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Patients on loop diuretics</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=55<br>1 (1.8%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=40<br>0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=31<br>3 (9.7%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=267<br>4 (1.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=236<br>6 (2.5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with eGFR â‰¥30 and &lt;60Â mL/min/1.73 m<span class="Sup">2</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=107<br>2 (1.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=107<br>1 (0.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=89<br>1 (1.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=268<br>4 (1.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=265<br>5 (1.9%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Patients â‰¥65 years of age</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=276<br>1 (0.4%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=216<br>1 (0.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=204<br>3 (1.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=711<br>6 (0.8%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=665<br>11 (1.7%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9b9c6820-5571-4471-ba89-6ca0692dbd47"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold">Impairment of Renal Function</span></h3>
<p class="First">Use of FARXIGA was associated with increases in serum creatinine and decreases in eGFR (see Table 3). In patients with normal or mildly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> at baseline, serum creatinine and eGFR returned to baseline values at Week 24. Renal-related adverse reactions, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4). Elderly patients and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> were more susceptible to these adverse reactions (see Table 4). Sustained decreases in eGFR were seen in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30 to less than 60Â mL/min/1.73 m<span class="Sup">2</span>).</p>
<a name="_RefID0EREAG"></a><table width="100%">
<caption><span>Table 3: Changes in Serum Creatinine and eGFR Associated with FARXIGA in the Pool of 12 Placebo-Controlled Studies and Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> Study</span></caption>
<col width="20%">
<col width="29%">
<col width="11%">
<col width="20%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Pool of 12 Placebo-Controlled Studies</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">N=1393</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">FARXIGA 5 mg</span><br><span class="Bold">N=1145</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">FARXIGA 10 mg</span><br><span class="Bold">N=1193</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Baseline Mean</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.853</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.860</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.847</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">86.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">85.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">86.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Week 1 Change</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.003</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.029</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.041</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’4.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Week 24 Change</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.005</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.001</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.3</p></td>
</tr>
<tr>
<td class="Lrule"></td>
<td></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First"><span class="Bold">Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> Study</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">N=84</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">FARXIGA 5 mg</span><br><span class="Bold">N=83</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">FARXIGA 10 mg</span><br><span class="Bold">N=85</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Baseline Mean</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.46</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.53</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.52</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">43.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Week 1 Change</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.01</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.13</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’3.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Week 24 Change</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.02</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.08</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.03</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’4.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’7.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Week 52 Change</p></td>
<td class="Botrule Lrule Rrule"><p class="First">Serum Creatinine (mg/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.10</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.06</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.15</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">eGFR (mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’4.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’7.3</p></td>
</tr>
</tbody>
</table>
<a name="_RefID0EFQAG"></a><table width="100%">
<caption><span>Table 4: Proportion of Patients with at Least One <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>-Related Adverse Reaction</span></caption>
<col width="40%">
<col width="10%">
<col width="11%">
<col width="11%">
<col width="13%">
<col width="15%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Pool of 6 Placebo-Controlled Studies</span><br><span class="Bold">(up to 104 weeks)*</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Pool of 9 Placebo-Controlled Studies</span><br><span class="Bold">(up to 104 weeks)<span class="Sup">â€ </span></span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Baseline Characteristic</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">5 mg</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">10 mg</span>
</th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">10 mg</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="11" valign="top">*Â Â Subset of patients from the pool of 12 placebo-controlled studies with long-term extensions.<br><span class="Sup">â€ </span>Â Â Subset of patients from the pool of 13 placebo-controlled studies with long-term extensions.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Overall population<br>Patients (%) with at least one event</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=785<br>13 (1.7%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=767<br>14 (1.8%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">n=859<br>16 (1.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">n=1956<br>82 (4.2%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">n=2026<br>136 (6.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">65 years of age and older <br>Patients (%) with at least one event</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=190<br>4 (2.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=162<br>5 (3.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=159<br>6 (3.8%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=655<br>52 (7.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=620<br>87 (14.0%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">eGFR â‰¥30 and &lt;60Â mL/min/1.73Â m<span class="Sup">2</span><br>Patients (%) with at least one event</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=77<br>5 (6.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=88<br>7 (8.0%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=75<br> 9 (12.0%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=249<br>40 (16.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=251<br>71 (28.3%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">65Â years of age and older and eGFR â‰¥30 and &lt;60Â mL/min/1.73Â m<span class="Sup">2</span><br>Patients (%) with at least one event</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=41<br><br>2 (4.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=43<br><br>3 (7.0%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">n=35<br><br>4 (11.4%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=141<br><br>27 (19.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">n=134<br><br>47 (35.1%)</p></td>
</tr>
</tbody>
</table>
<p>The safety of FARXIGA was evaluated in a study of patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30 to less than 60 mL/min/1.73 m<span class="Sup">2</span>) [see <span class="Italics"><a href="#ID_76c6053f-7492-4388-8eb8-2b250575b5f0">Clinical Studies (14)</a></span>]. In this study 13 patients experienced bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> for treatment durations up to 104 weeks. No <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> occurred in the placebo group, 5 occurred in the FARXIGA 5 mg group, and 8 occurred in the FARXIGA 10 mg group. Eight of these 13 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were in patients who had a baseline eGFR of 30 to 45Â mL/min/1.73Â m<span class="Sup">2</span>. Eleven of the 13 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were reported within the first 52 weeks. There was no apparent pattern with respect to the anatomic site of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4cb8cc9d-cd69-4b10-92aa-3eaa217e1760"></a><a name="section-6.1.5"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></h3>
<p class="First">The frequency of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> by study [see <span class="Italics"><a href="#ID_76c6053f-7492-4388-8eb8-2b250575b5f0">Clinical Studies (14)</a></span>] is shown in Table 5. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was more frequent when FARXIGA was added to sulfonylurea or insulin [see <span class="Italics"><a href="#ID_e900c648-db48-4beb-9b59-f996eba00d94">Warnings and Precautions (5.3)</a></span>].</p>
<a name="_RefID0EI1AG"></a><table width="100%">
<caption><span>Table 5: Incidence of Major* and Minor<span class="Sup">â€ </span> <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> in Placebo-Controlled Studies</span></caption>
<col width="57%">
<col width="10%">
<col width="16%">
<col width="17%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">FARXIGA 5 mg</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">FARXIGA 10 mg</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Major episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value &lt;54 mg/dL and prompt recovery after glucose or glucagon administration.<br><span class="Sup">â€ </span>Â Â Minor episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were defined as either a symptomatic episode with a capillary or plasma glucose measurement &lt;63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement &lt;63 mg/dL that does not qualify as a major episode.<br><span class="Sup">â€¡</span>Â Â OAD = oral antidiabetic therapy.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Monotherapy* (24 weeks)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">N=75</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">N=64</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">N=70</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Add-on to Metformin* (24 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=137</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=137</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=135</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (1.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Active Control Add-on to Metformin versus Glipizide (52 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=408</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">â€“</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=406</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.7)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">147 (36.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (1.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Add-on to Glimepiride* (24 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=146</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=145</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=151</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (2.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8 (5.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (6.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Add-on to Pioglitazone* (24 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=139</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=141</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=140</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (2.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Add-on to DPP4 inhibitor (24 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=226</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">â€“</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=225</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (1.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4 (1.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Add-on to Insulin with or without other OADs<span class="Sup">â€¡</span> (24 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=197</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=212</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=196</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Major [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Minor [n (%)]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">67 (34.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">92 (43.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">79 (40.3)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e923af5d-f3de-4963-be0c-b41e14cf3485"></a><a name="section-6.1.6"></a><p></p>
<h3><span class="Bold">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></h3>
<p class="First">Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more frequent with FARXIGA treatment. Genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported in 0.9% of patients on placebo, 5.7% on FARXIGA 5 mg, and 4.8% on FARXIGA 10 mg, in the 12-study placebo-controlled pool. Discontinuation from study due to <span class="product-label-link" type="condition" conceptid="4193988" conceptname="Genital infection">genital infection</span> occurred in 0% of placebo-treated patients and 0.2% of patients treated with FARXIGA 10 mg. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> were more frequently reported in females than in males (see Table 1). The most frequently reported genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in females and <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> in males. Patients with a history of genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were more likely to have a genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during the study than those with no prior history (10.0%, 23.1%, and 25.0% versus 0.8%, 5.9%, and 5.0% on placebo, FARXIGA 5 mg, and FARXIGA 10 mg, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_07b573a5-9ce2-492b-b57f-bdec19ff6b34"></a><a name="section-6.1.7"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) were reported with FARXIGA treatment. Across the clinical program, serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and severe cutaneous adverse reactions and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> were reported in 0.2% of comparator-treated patients and 0.3% of FARXIGA-treated patients. If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur, discontinue use of FARXIGA; treat per standard of care and monitor until signs and symptoms resolve.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="ID_7f597654-16ea-443e-8c5d-8157e26500c7"></a><a name="section-6.1.8"></a><p></p>
<h3><span class="Bold">Laboratory Tests</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7f9bebbd-9dcc-43cb-89d9-2c9180abd6e7"></a><a name="section-6.1.8.1"></a><p></p>
<h4><span class="Bold">Increase in Hematocrit</span></h4>
<p class="First">In the pool of 13 placebo-controlled studies, increases from baseline in mean hematocrit values were observed in FARXIGA-treated patients starting at Week 1 and continuing up to Week 16, when the maximum mean difference from baseline was observed. At Week 24, the mean changes from baseline in hematocrit were âˆ’0.33% in the placebo group and 2.30% in the FARXIGA 10 mg group. By Week 24, hematocrit values &gt;55% were reported in 0.4% of placebo-treated patients and 1.3% of FARXIGA 10Â mgâ€“treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_25d940cf-be1f-4549-b734-5303ebd6ce2b"></a><a name="section-6.1.8.2"></a><p></p>
<h4><span class="Bold">Increase in Serum Inorganic Phosphorus</span></h4>
<p class="First">In the pool of 13 placebo-controlled studies, increases from baseline in mean serum phosphorus levels were reported at Week 24 in FARXIGA-treated patients compared with placebo-treated patients (mean increase of 0.13 versus âˆ’0.04 mg/dL, respectively). Higher proportions of patients with marked laboratory abnormalities of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> (â‰¥5.6 mg/dL for age 17-65 years or â‰¥5.1 mg/dL for age â‰¥66 years) were reported on FARXIGA at Week 24 (0.9% versus 1.7% for placebo and FARXIGA 10 mg, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f46cdbde-4d86-4631-aa67-c6eebe5df82b"></a><a name="section-6.1.8.3"></a><p></p>
<h4><span class="Bold">Increase in Low-Density Lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></h4>
<p class="First">In the pool of 13 placebo-controlled studies, changes from baseline in mean lipid values were reported in FARXIGA-treated patients compared to placebo-treated patients. Mean percent changes from baseline at Week 24, were 0.0% versus 2.5% for total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and âˆ’1.0% versus 2.9% for LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, in the placebo and FARXIGA 10 mg groups, respectively.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_86678d0b-ecfc-4565-affb-4fbf030fdb3c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_26866362-e530-450a-ba15-07036da3d3bf"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Positive Urine Glucose Test</h2>
<p class="First">Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b917c756-d2db-4dd3-bd11-b84166d4e5ab"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Interference with 1,5-anhydroglucitol (1,5-AG) Assay</h2>
<p class="First">Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_c91ba92e-5fd4-403e-88c2-8c75049babc3"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_631c78c9-089e-4252-9ff5-deed29b21c97"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_501eaed2-5014-4eb2-b9c0-fb452af2b9b8"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C</span></h3>
<p class="First">There are no adequate and well-controlled studies of FARXIGA in pregnant women. Based on results of reproductive and developmental toxicity studies in animals, dapagliflozin may affect renal development and maturation. In a juvenile rat study, increased incidence and/or severity of renal pelvic and tubular dilatations were evident at the lowest tested dose which was approximately 15 times clinical exposure from a 10 mg dose.</p>
<p>These outcomes occurred with drug exposures during periods of animal development that correlate with the late second and third trimesters of human pregnancy. During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters. FARXIGA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In a juvenile toxicity study, when dapagliflozin was dosed directly to young rats from postnatal day (PND) 21 until PND 90 at doses of 1, 15, or 75 mg/kg/day, increased kidney weights and renal pelvic and tubular dilatations were reported at all levels. Exposure at the lowest tested dose was 15 times the maximum clinical dose, based on AUC. The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within the approximate 1-month recovery period. </p>
<p>In a prenatal and postnatal development study, maternal rats were dosed from gestation day 6 through lactation day 21 at doses of 1, 15, or 75 mg/kg/day, and pups were indirectly exposed <span class="Italics">in utero</span> and throughout lactation. Increased incidence or severity of renal pelvic dilatation was observed in adult offspring of treated dams at 75 mg/kg/day (maternal and pup dapagliflozin exposures were 1415 times and 137 times, respectively, the human values at the clinical dose). Dose-related reductions in pup body weights were observed at doses â‰¥1 mg/kg/day (approximately â‰¥19 times the clinical dose). No adverse effects on developmental endpoints were noted at 1 mg/kg/day, or approximately 19 times the clinical dose.</p>
<p>In embryo-fetal development studies in rats and rabbits, dapagliflozin was administered for intervals coinciding with the first trimester period of organogenesis in humans. No developmental toxicities were observed in rabbits at any dose tested. In rats, dapagliflozin was neither embryolethal nor teratogenic at doses up to 75 mg/kg/day or 1441 times the maximum clinical dose of 10 mg. At higher doses in rats, malformations of blood vessels, ribs, vertebra, manubria, and skeletal variations in fetuses at â‰¥150 mg/kg or 2344 times the 10 mg clinical dose were observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_e20f5b2a-a410-410f-ad4d-10bbb72bde0d"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether FARXIGA is excreted in human milk. Dapagliflozin is excreted in rat milk reaching levels 0.49 times that found in maternal plasma. Data in juvenile rats directly exposed to dapagliflozin showed risk to the developing kidney (renal pelvic and tubular dilatations) during maturation. Since human kidney maturation occurs <span class="Italics">in utero</span> and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from FARXIGA, a decision should be made whether to discontinue nursing or to discontinue FARXIGA, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_51ccff08-978b-4765-a61c-a432dbba7f5f"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of FARXIGA in pediatric patients under 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_4a4f094a-f6b5-4b8e-8e00-34e712bc2c4e"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No FARXIGA dosage change is recommended based on age. A total of 1424 (24%) of the 5936 FARXIGA-treated patients were 65 years and older and 207 (3.5%) patients were 75 years and older in a pool of 21 double-blind, controlled, clinical safety and efficacy studies of FARXIGA. After controlling for level of renal function (eGFR), efficacy was similar for patients under age 65 years and those 65 years and older. In patients â‰¥65 years of age, a higher proportion of patients treated with FARXIGA had adverse reactions related to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or failure compared to patients treated with placebo [see <span class="Italics"><a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_40fa6b7d-6302-4cb3-9914-8fdd42b33f34"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The safety and efficacy of FARXIGA were evaluated in a study that included patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR 30 to less than 60 mL/min/1.73 m<span class="Sup">2</span>). Compared to placebo-treated patients, patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> treated with FARXIGA did not have improvement in glycemic control [see <span class="Italics"><a href="#ID_03b9ef1c-1e30-4ac8-9d70-4596853aa4db">Clinical Studies (14.7)</a></span>] and had more renal-related adverse reactions and more bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> [see <span class="Italics"><a href="#_Ref">Dosage and Administration (2.2)</a></span>, <span class="Italics"><a href="#ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393">Warnings and Precautions (5.2)</a></span>, and <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>]; therefore, FARXIGA should not be initiated in this population.</p>
<p>Based on its mechanism of action, FARXIGA is not expected to be effective in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (eGFR less than 30 mL/min/1.73 m<span class="Sup">2</span>) or ESRD [see <span class="Italics"><a href="#ID_81425830-0e2c-411d-9e4c-5c09c6eca667">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb31896c-0d39-4ed2-b212-3b17ae29a19f"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment is recommended for patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. However, the benefit-risk for the use of dapagliflozin in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be individually assessed since the safety and efficacy of dapagliflozin have not been specifically studied in this population [see <span class="Italics"><a href="#ID_adafb2c0-d411-434d-8473-381d0f10b0ea">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_beb12230-5c4d-4c56-b90b-a03a3e013b81"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There were no reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> during the clinical development program for FARXIGA.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, contact the Poison Control Center. It is also reasonable to employ supportive measures, as dictated by the patientâ€™s clinical status. The removal of dapagliflozin by hemodialysis has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_fd36fb00-7c31-4b1a-ad48-5d227ed82c01"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Dapagliflozin is described chemically as D-glucitol, 1,5-anhydro-1-<span class="Italics">C</span>-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1<span class="Italics">S</span>)-, compounded with (2<span class="Italics">S</span>)-1,2-propanediol, hydrate (1:1:1). The empirical formula is C<span class="Sub">21</span>H<span class="Sub">25</span>ClO<span class="Sub">6</span>â€¢C<span class="Sub">3</span>H<span class="Sub">8</span>O<span class="Sub">2</span>â€¢H<span class="Sub">2</span>O and the molecular weight is 502.98. The structural formula is:</p>
<div class="Figure">
<a name="id6857421"></a><img alt="Dapagliflozin Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998&amp;name=dapagliflozin-struct.jpg">
</div>
<p>FARXIGA is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_6322be21-1db0-4218-8301-583bf5813262"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_cabd478b-f4e0-4776-a12b-16ef3def0ff7"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_4ff619d4-4d28-4562-83af-e97d8194111c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_34cbef1c-607b-4d02-ae7b-c219d9b29f51"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold">General</span></h3>
<p class="First">Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus following the administration of dapagliflozin (see Figure 1). Dapagliflozin dose of 10 mg per day in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at Week 12. A near maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume [see <span class="Italics"><a href="#ID_d97c96c1-cba2-4488-94a0-fba9d0192c1e">Adverse Reactions (6.1)</a></span>].</p>
<p><span class="Bold">Figure 1: Scatter Plot and Fitted Line of Change from Baseline in 24-Hour Urinary Glucose Amount versus Dapagliflozin Dose in Healthy Subjects and Subjects with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (T2DM) (Semi-Log Plot)</span></p>
<div class="Figure">
<a name="id6857474"></a><img alt="Farxiga Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998&amp;name=farxiga-fig1.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1d8377dd-3e19-40cf-826b-3d8f0178fcb8"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold">Cardiac Electrophysiology</span></h3>
<p class="First">Dapagliflozin was not associated with clinically meaningful prolongation of QTc interval at daily doses up to 150 mg (15 times the recommended maximum dose) in a study of healthy subjects. In addition, no clinically meaningful effect on QTc interval was observed following single doses of up to 500Â mg (50 times the recommended maximum dose) of dapagliflozin in healthy subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_adafb2c0-d411-434d-8473-381d0f10b0ea"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bd8cd896-c540-4554-b8aa-e8e757d62629"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">Following oral administration of dapagliflozin, the maximum plasma concentration (C<span class="Sub">max</span>) is usually attained within 2 hours under fasting state. The C<span class="Sub">max</span> and AUC values increase dose proportionally with increase in dapagliflozin dose in the therapeutic dose range. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%. Administration of dapagliflozin with a high-fat meal decreases its C<span class="Sub">max </span>by up to 50% and prolongs T<span class="Sub">max</span> by approximately 1 hour, but does not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful and dapagliflozin can be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cb0a5f26-e271-44ca-b6c2-980765f27bb2"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">Dapagliflozin is approximately 91% protein bound. Protein binding is not altered in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d19c7a3a-05eb-4d20-9910-5909fe8d8841"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">The metabolism of dapagliflozin is primarily mediated by UGT1A9; CYP-mediated metabolism is a minor clearance pathway in humans. Dapagliflozin is extensively metabolized, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite. Dapagliflozin 3-O-glucuronide accounted for 61% of a 50 mg [14C]-dapagliflozin dose and is the predominant drug-related component in human plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9c2fd52a-2668-4e13-bf16-cb254a003f47"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Bold">Elimination</span></h3>
<p class="First">Dapagliflozin and related metabolites are primarily eliminated via the renal pathway. Following a single 50 mg dose of [14C]-dapagliflozin, 75% and 21% total radioactivity is excreted in urine and feces, respectively. In urine, less than 2% of the dose is excreted as parent drug. In feces, approximately 15% of the dose is excreted as parent drug. The mean plasma terminal half-life (t<span class="Sub">Â½</span>) for dapagliflozin is approximately 12.9 hours following a single oral dose of FARXIGA 10Â mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8fd14de3-de24-4a35-87aa-bf27a9f6ce22"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a682a4b8-5031-44b3-9ace-3a935b003a1a"></a><a name="section-11.3.5.1"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h4>
<p class="First">At steady state (20 mg once-daily dapagliflozin for 7 days), patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (as determined by eGFR) had geometric mean systemic exposures of dapagliflozin that were 45%, 2.04-fold, and 3.03-fold higher, respectively, as compared to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with normal renal function. Higher systemic exposure of dapagliflozin in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> did not result in a correspondingly higher 24-hour urinary glucose excretion. The steady-state 24-hour urinary glucose excretion in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was 42%, 80%, and 90% lower, respectively, than patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with normal renal function. The impact of hemodialysis on dapagliflozin exposure is not known. [See <span class="Italics"><a href="#ID_8dbfb145-ce00-4958-be5d-b50f7f9faf68">Dosage and Administration (2.2)</a></span>, <span class="Italics"><a href="#ID_6d76ab5b-5c32-41ae-b088-e4f3d9e6b393">Warnings and Precautions (5.2)</a></span>, <span class="Italics"><a href="#ID_40fa6b7d-6302-4cb3-9914-8fdd42b33f34">Use in Specific Populations (8.6)</a></span>, and <span class="Italics"><a href="#ID_03b9ef1c-1e30-4ac8-9d70-4596853aa4db">Clinical Studies (14.7)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1f47a8f9-24e4-49b8-bcd8-fe7f56c1e81e"></a><a name="section-11.3.5.2"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h4>
<p class="First">In subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh classes A and B), mean C<span class="Sub">max</span> and AUC of dapagliflozin were up to 12% and 36% higher, respectively, as compared to healthy matched control subjects following single-dose administration of 10 mg dapagliflozin. These differences were not considered to be clinically meaningful. In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C), mean C<span class="Sub">max</span> and AUC of dapagliflozin were up to 40% and 67% higher, respectively, as compared to healthy matched controls [see <span class="Italics"><a href="#ID_eb31896c-0d39-4ed2-b212-3b17ae29a19f">Use in Specific Populations (8.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8bdb4351-cdb8-4d54-ad9b-f7c0fe0c1a59"></a><a name="section-11.3.5.3"></a><p></p>
<h4><span class="Bold">Effects of Age, Gender, Race, and Body Weight on Pharmacokinetics</span></h4>
<p class="First">Based on a population pharmacokinetic analysis, age, gender, race, and body weight do not have a clinically meaningful effect on the pharmacokinetics of dapagliflozin and thus, no dose adjustment is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_307976b4-8855-4f88-8616-3e76860c788e"></a><a name="section-11.3.5.4"></a><p></p>
<h4><span class="Bold">Pediatric</span></h4>
<p class="First">Pharmacokinetics in the pediatric population has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b41c7133-4630-4483-9328-45b486147434"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Bold">Drug Interactions</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b700ca2-5e81-4796-a1f9-43a4a848c7e4"></a><a name="section-11.3.6.1"></a><p></p>
<h4><span class="Bold">In Vitro Assessment of Drug Interactions</span></h4>
<p class="First">In <span class="Italics">in vitro </span>studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, or 3A4, nor induced CYP 1A2, 2B6, or 3A4. Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter. Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4a93f4d-2433-4f6c-83f3-ed85d0a3affc"></a><a name="section-11.3.6.2"></a><p></p>
<h4><span class="Bold">Effects of Other Drugs on Dapagliflozin</span></h4>
<p class="First">Table 6 shows the effect of coadministered drugs on the pharmacokinetics of dapagliflozin. No dose adjustments are recommended for dapagliflozin.</p>
<a name="_RefID0EN5BG"></a><table width="100%">
<caption><span>Table 6: Effects of Coadministered Drugs on Dapagliflozin Systemic Exposure</span></caption>
<col width="59%">
<col width="16%">
<col width="13%">
<col width="13%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<span class="Bold">Coadministered Drug</span><br><span class="Bold">(Dose Regimen)*</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">Dapagliflozin</span><br><span class="Bold">(Dose Regimen)*</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Effect on Dapagliflozin Exposure</span><br><span class="Bold">(% Change [90% CI])</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">AUC<span class="Sup">â€ </span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Single dose unless otherwise noted.<br><span class="Sup">â€ </span>Â Â AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.<br>â†” = no change (geometric mean ratio of test:reference within 0.80 to 1.25); â†“ or â†‘ = parameter was lower or higher, respectively, with coadministration compared to dapagliflozin administered alone (geometric mean ratio of test:reference was lower than 0.80 or higher than 1.25).</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">No dosing adjustments required for the following:</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Oral Antidiabetic Agents</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Metformin (1000 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Pioglitazone (45 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Sitagliptin (100 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Glimepiride (4 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Voglibose (0.2 mg three times daily)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Other Medications</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Hydrochlorothiazide (25 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Bumetanide (1 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg once daily<br>for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Valsartan (320 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“12%<br>[â†“3%, â†“20%]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Simvastatin (40 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Anti-infective Agent</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Rifampin (600 mg once daily for 6 days)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“7%<br>[â†“22%, â†‘11%]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“22%<br>[â†“27%, â†“17%]</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Nonsteroidal Anti-inflammatory Agent</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Mefenamic Acid (loading dose of 500Â mg followed by 14 doses of 250 mg every 6 hours)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘13%<br>[â†‘3%, â†‘24%]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘51%<br>[â†‘44%, â†‘58%]</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f220edee-033e-4b82-8daf-75957b1c0c3d"></a><a name="section-11.3.6.3"></a><p></p>
<h4><span class="Bold">Effects of Dapagliflozin on Other Drugs</span></h4>
<p class="First">Table 7 shows the effect of dapagliflozin on other coadministered drugs. Dapagliflozin did not meaningfully affect the pharmacokinetics of the coadministered drugs.</p>
<a name="_RefID0ELIAI"></a><table width="100%">
<caption><span>Table 7: Effects of Dapagliflozin on the Systemic Exposures of Coadministered Drugs</span></caption>
<col width="32%">
<col width="24%">
<col width="22%">
<col width="22%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<span class="Bold">Coadministered Drug</span><br><span class="Bold">(Dose Regimen)*</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">Dapagliflozin</span><br><span class="Bold">(Dose Regimen)*</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Effect on Coadministered Drug Exposure</span><br><span class="Bold">(% Change [90% CI])</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">C<span class="Sub">max</span></span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">AUC<span class="Sup">â€ </span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Single dose unless otherwise noted.<br><span class="Sup">â€ </span>Â Â AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses.<br>â†” = no change (geometric mean ratio of test:reference within 0.80 to 1.25); â†“ or â†‘ = parameter was lower or higher, respectively, with coadministration compared to dapagliflozin administered alone (geometric mean ratio of test:reference was lower than 0.80 or higher than 1.25).</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">No dosing adjustments required for the following:</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Oral Antidiabetic Agents</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Metformin (1000 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Pioglitazone (45 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“7%<br>[â†“25%, â†‘15%]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Sitagliptin (100 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Glimepiride (4 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘13%<br>[0%, â†‘29%]</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Other Medications</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Hydrochlorothiazide (25 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Bumetanide (1 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 mg once daily<br>for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘13%<br>[â†“2%, â†‘31%]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘13%<br>[â†“1%, â†‘30%]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Valsartan (320 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†“6%<br>[â†“24%, â†‘16%]</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘5%<br>[â†“15%, â†‘29%]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Simvastatin (40 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†‘19%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Digoxin (0.25 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg loading dose<br>then 10 mg once daily<br>for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Warfarin (25 mg)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 mg loading dose<br>then 10 mg once daily<br>for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â†”</p></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_711c4f00-750a-4bd4-9d10-e0650bb1f188"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_0bc0aa1a-cbc3-4214-85af-59dff801e58d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Dapagliflozin did not induce tumors in either mice or rats at any of the doses evaluated in 2-year carcinogenicity studies. Oral doses in mice consisted of 5, 15, and 40 mg/kg/day in males and 2, 10, and 20 mg/kg/day in females, and oral doses in rats were 0.5, 2, and 10 mg/kg/day for both males and females. The highest doses evaluated in mice were approximately 72 times (males) and 105 times (females) the clinical dose of 10 mg per day based on AUC exposure. In rats, the highest dose was approximately 131 times (males) and 186 times (females) the clinical dose of 10 mg per day based on AUC exposure.</p>
<p>Dapagliflozin was negative in the Ames mutagenicity assay and was positive in a series of <span class="Italics">in vitro</span> clastogenicity assays in the presence of S9 activation and at concentrations â‰¥100Â Î¼g/mL. Dapagliflozin was negative for clastogenicity in a series of <span class="Italics">in vivo</span> studies evaluating micronuclei or DNA repair in rats at exposure multiples &gt;2100 times the clinical dose.</p>
<p>There was no carcinogenicity or mutagenicity signal in animal studies, suggesting that dapagliflozin does not represent a genotoxic risk to humans.</p>
<p>Dapagliflozin had no effects on mating, fertility, or early embryonic development in treated male or female rats at exposure multiples â‰¤1708 times and 998 times the maximum recommended human dose in males and females, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_76c6053f-7492-4388-8eb8-2b250575b5f0"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4096970-90bd-47d3-8642-900b00ef9fc3"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Overview of Clinical Studies of FARXIGA for Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">FARXIGA has been studied as monotherapy and in combination with metformin, pioglitazone, glimepiride, sitagliptin (with or without metformin), or insulin (with or without other oral antidiabetic therapy). The efficacy of FARXIGA was compared to a sulfonylurea (glipizide) added on to metformin. FARXIGA has also been studied in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Treatment with FARXIGA as monotherapy and in combination with metformin, glimepiride, pioglitazone, sitagliptin, or insulin produced statistically significant improvements in mean change from baseline at Week 24 in HbA1c compared to control. Reductions in HbA1c were seen across subgroups including gender, age, race, duration of disease, and baseline BMI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f7ce5a96-caa4-4b1c-a007-5ae23ff3e56b"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Monotherapy</h2>
<p class="First">A total of 840 treatment-naive patients with inadequately controlled type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in 2 placebo-controlled studies to evaluate the safety and efficacy of monotherapy with FARXIGA.</p>
<p>In 1 monotherapy study, a total of 558 treatment-naive patients with inadequately controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in a 24-week study. Following a 2-week diet and exercise placebo lead-in period, 485 patients with HbA1c â‰¥7% and â‰¤10% were randomized to FARXIGA 5 mg or FARXIGA 10 mg once daily in either the morning (QAM, main cohort) or evening (QPM), or placebo.</p>
<p>At Week 24, treatment with FARXIGA 10 mg QAM provided significant improvements in HbA1c and FPG compared with placebo (see Table 8). </p>
<a name="_RefID0EYTAI"></a><table width="100%">
<caption><span>Table 8: Results at Week 24 (LOCF*) in a Placebo-Controlled Study of FARXIGA Monotherapy in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (Main Cohort AM Doses)</span></caption>
<col width="47%">
<col width="22%">
<col width="20%">
<col width="11%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA 10 mg</span><br><span class="Bold">N=70<span class="Sup">â€ </span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA 5 mg</span><br><span class="Bold">N=64<span class="Sup">â€ </span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">N=75<span class="Sup">â€ </span></span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â LOCF: last observation (prior to rescue for rescued patients) carried forward.<br><span class="Sup">â€ </span>Â Â All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period.<br><span class="Sup">â€¡</span>Â Â Least squares mean adjusted for baseline value.<br><span class="Sup">Â§</span>Â Â p-value &lt;0.0001 versus placebo. Sensitivity analyses yielded smaller estimates of treatment difference with placebo.<br><span class="Sup">Â¶</span>Â Â Not evaluated for statistical significance as a result of the sequential testing procedure for the secondary endpoints.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.7<span class="Sup">Â§</span><br>(âˆ’1.0, âˆ’0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5<br>(âˆ’0.8, âˆ’0.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Percent of patients achieving HbA1c &lt;7% <br>Â Â adjusted for baseline</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50.8%<span class="Sup">Â¶</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">44.2%<span class="Sup">Â¶</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31.6%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">166.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">157.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">159.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’28.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’24.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’4.1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’24.7<span class="Sup">Â§</span><br>(âˆ’35.7, âˆ’13.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’19.9<br>(âˆ’31.3, âˆ’8.5)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1417e1f4-2fe2-405c-9923-1bff83dd0de5"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Initial Combination Therapy with Metformin</h2>
<p class="First">A total of 1241 treatment-naive patients with inadequately controlled type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (HbA1c â‰¥7.5% and â‰¤12%) participated in 2 active-controlled studies of 24-week duration to evaluate the safety and efficacy of initial therapy with FARXIGA 5 mg or 10 mg in combination with metformin extended-release (XR) formulation.</p>
<p>In 1 study, 638 patients were randomized to 1 of 3 treatment arms following a 1-week lead-in period: FARXIGA 10 mg plus metformin XR (up to 2000 mg per day), FARXIGA 10 mg plus placebo, or metformin XR (up to 2000 mg per day) plus placebo. Metformin XR dose was up-titrated weekly in 500 mg increments, as tolerated, with a median dose achieved of 2000 mg.</p>
<p>The combination treatment of FARXIGA 10 mg plus metformin XR provided statistically significant improvements in HbA1c and FPG compared with either of the monotherapy treatments and statistically significant reduction in body weight compared with metformin XR alone (see Table 9 and Figure 2). FARXIGA 10 mg as monotherapy also provided statistically significant improvements in FPG and statistically significant reduction in body weight compared with metformin alone and was noninferior to metformin XR monotherapy in lowering HbA1c.</p>
<a name="_RefID0EN2AI"></a><table width="100%">
<caption><span>Table 9: Results at Week 24 (LOCF*) in an Active-Controlled Study of FARXIGA Initial Combination Therapy with Metformin XR</span></caption>
<col width="49%">
<col width="19%">
<col width="15%">
<col width="17%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">10 mg</span><br><span class="Bold">+ Metformin XR</span>
</th>
<th class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA </span><br><span class="Bold">10 mg</span>
</th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Metformin XR</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">N=211<span class="Sup">â€ </span></span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">N=219<span class="Sup">â€ </span></span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">N=208<span class="Sup">â€ </span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â LOCF: last observation (prior to rescue for rescued patients) carried forward.<br><span class="Sup">â€ </span>Â Â All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period.<br><span class="Sup">â€¡</span>Â Â Least squares mean adjusted for baseline value.<br><span class="Sup">Â§</span>Â Â p-value &lt;0.0001.<br><span class="Sup">Â¶</span>Â Â Noninferior versus metformin XR.<br><span class="Sup">#</span>Â Â p-value &lt;0.05.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from FARXIGA (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5<span class="Sup">Â§</span><br>(âˆ’0.7, âˆ’0.3)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from metformin XR (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5<span class="Sup">Â§</span><br>(âˆ’0.8, âˆ’0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.0<span class="Sup">Â¶</span><br>(âˆ’0.2, 0.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Percent of patients achieving HbA1c &lt;7% <br>Â Â adjusted for baseline</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46.6%<span class="Sup">#</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31.7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35.2%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">189.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">197.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">189.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’60.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’46.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’34.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from FARXIGA (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’13.9<span class="Sup">Â§</span><br>(âˆ’20.9, âˆ’7.0)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from metformin XR (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’25.5<span class="Sup">Â§</span><br>(âˆ’32.6, âˆ’18.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’11.6<span class="Sup">#</span><br>(âˆ’18.6, âˆ’4.6)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">88.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">88.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">87.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’3.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from metformin XR (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.0<span class="Sup">Â§</span><br>(âˆ’2.6, âˆ’1.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.4<span class="Sup">Â§</span><br>(âˆ’2.0, âˆ’0.7)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 2: Adjusted Mean Change from Baseline Over Time in HbA1c (%) in a 24-Week Active-Controlled Study of FARXIGA Initial Combination Therapy with Metformin XR</span></p>
<div class="Figure">
<a name="id50799848"></a><img alt="FARXIGA Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998&amp;name=farxiga-fig2.jpg">
</div>
<p>In a second study, 603 patients were randomized to 1 of 3 treatment arms following a 1-week lead-in period: FARXIGA 5 mg plus metformin XR (up to 2000 mg per day), FARXIGA 5 mg plus placebo, or metformin XR (up to 2000 mg per day) plus placebo. Metformin XR dose was up-titrated weekly in 500 mg increments, as tolerated, with a median dose achieved of 2000 mg.</p>
<p>The combination treatment of FARXIGA 5 mg plus metformin XR provided statistically significant improvements in HbA1c and FPG compared with either of the monotherapy treatments and statistically significant reduction in body weight compared with metformin XR alone (see Table 10).</p>
<a name="_RefID0EFHBI"></a><table width="100%">
<caption><span>Table 10: Results at Week 24 (LOCF*) in an Active-Controlled Study of FARXIGA Initial Combination Therapy with Metformin XR</span></caption>
<col width="50%">
<col width="19%">
<col width="13%">
<col width="17%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA </span><br><span class="Bold">5 mg </span><br><span class="Bold">+ Metformin XR</span>
</th>
<th class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA </span><br><span class="Bold">5 mg</span>
</th>
<th class="Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Metformin XR</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">N=194<span class="Sup">â€ </span></span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">N=203<span class="Sup">â€ </span></span></th>
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">N=201<span class="Sup">â€ </span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="8" valign="top">*Â Â LOCF: last observation (prior to rescue for rescued patients) carried forward.<br><span class="Sup">â€ </span>Â Â All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period.<br><span class="Sup">â€¡</span>Â Â Least squares mean adjusted for baseline value.<br><span class="Sup">Â§</span>Â Â p-value &lt;0.0001.<br><span class="Sup">Â¶</span>Â Â p-value &lt;0.05.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from FARXIGA (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.9<span class="Sup">Â§</span><br>(âˆ’1.1, âˆ’0.6)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from metformin XR (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.7<span class="Sup">Â§</span><br>(âˆ’0.9, âˆ’0.5)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Percent of patients achieving HbA1c &lt;7% <br>Â Â adjusted for baseline</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">52.4%<span class="Sup">Â¶</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22.5%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">34.6%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">193.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">190.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">196.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’61.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’42.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’33.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from FARXIGA (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’19.1<span class="Sup">Â§</span><br>(âˆ’26.7, âˆ’11.4)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from metformin XR (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’27.5<span class="Sup">Â§</span><br>(âˆ’35.1, âˆ’19.8)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">84.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">86.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">85.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from metformin XR (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.4<span class="Sup">Â§</span><br>(âˆ’2.0, âˆ’0.7)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e332d981-ef2c-48e6-93c5-9daf31c1a19a"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Add-On to Metformin</h2>
<p class="First">A total of 546 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with inadequate glycemic control (HbA1c â‰¥7% and â‰¤10%) participated in a 24-week, placebo-controlled study to evaluate FARXIGA in combination with metformin. Patients on metformin at a dose of at least 1500 mg per day were randomized after completing a 2-week, single-blind, placebo lead-in period. Following the lead-in period, eligible patients were randomized to FARXIGA 5 mg, FARXIGA 10 mg, or placebo in addition to their current dose of metformin.</p>
<p>As add-on treatment to metformin, FARXIGA 10 mg provided statistically significant improvements in HbA1c and FPG, and statistically significant reduction in body weight compared with placebo at Week 24 (see Table 11 and Figure 3). Statistically significant (p&lt;0.05 for both doses) mean changes from baseline in systolic blood pressure relative to placebo plus metformin were âˆ’4.5 mmHg and âˆ’5.3 mmHg with FARXIGA 5 mg and 10 mg plus metformin, respectively.</p>
<a name="_RefID0EYSBI"></a><table width="100%">
<caption><span>Table 11: Results of a 24-Week (LOCF*) Placebo-Controlled Study of FARXIGA in Add-On Combination with Metformin</span></caption>
<col width="49%">
<col width="19%">
<col width="18%">
<col width="14%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA 10 mg </span><br><span class="Bold">+ Metformin </span><br><span class="Bold">N=135<span class="Sup">â€ </span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA 5 mg </span><br><span class="Bold">+ Metformin </span><br><span class="Bold">N=137<span class="Sup">â€ </span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">+ Metformin </span><br><span class="Bold">N=137<span class="Sup">â€ </span></span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â LOCF: last observation (prior to rescue for rescued patients) carried forward.<br><span class="Sup">â€ </span>Â Â All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period.<br><span class="Sup">â€¡</span>Â Â Least squares mean adjusted for baseline value.<br><span class="Sup">Â§</span>Â Â p-value &lt;0.0001 versus placebo + metformin.<br><span class="Sup">Â¶</span>Â Â p-value &lt;0.05 versus placebo + metformin.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from placebo (adjusted mean<span class="Sup">â€¡</span>)<br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5<span class="Sup">Â§</span><br>(âˆ’0.7, âˆ’0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.4<span class="Sup">Â§</span><br>(âˆ’0.6, âˆ’0.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Percent of patients achieving HbA1c &lt;7% <br>Â Â adjusted for baseline</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">40.6%<span class="Sup">Â¶</span><br></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37.5%<span class="Sup">Â¶</span><br></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">25.9%<br></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">156.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">169.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">165.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline at Week 24 (adjusted mean<span class="Sup">â€¡</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’23.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’21.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’6.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’17.5<span class="Sup">Â§</span><br>(âˆ’25.0, âˆ’10.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’15.5<span class="Sup">Â§</span><br> (âˆ’22.9, âˆ’8.1)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline at Week 1 (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’16.5<span class="Sup">Â§</span><br>(N=115)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’12.0<span class="Sup">Â§</span><br>(N=121)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.2<br>(N=126)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">86.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">84.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">87.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’3.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.9</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from placebo (adjusted mean<span class="Sup">â€¡</span>)<br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.0<span class="Sup">Â§</span><br> (âˆ’2.6, âˆ’1.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.2<span class="Sup">Â§</span><br> (âˆ’2.8, âˆ’1.5)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 3: Adjusted Mean Change from Baseline Over Time in HbA1c (%) in a 24-Week Placebo-Controlled Study of FARXIGA in Combination with Metformin</span></p>
<div class="Figure">
<a name="id50816895"></a><img alt="FARXIGA Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998&amp;name=farxiga-fig3.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f0328fa-7ff2-4ec1-8059-522aba234a55"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Active Glipizide-Controlled Study Add-On to Metformin</h2>
<p class="First">A total of 816 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with inadequate glycemic control (HbA1c &gt;6.5% and â‰¤10%) were randomized in a 52-week, glipizide-controlled, noninferiority study to evaluate FARXIGA as add-on therapy to metformin. Patients on metformin at a dose of at least 1500 mg per day were randomized following a 2-week placebo lead-in period to glipizide or dapagliflozin (5 mg or 2.5 mg, respectively) and were up-titrated over 18 weeks to optimal glycemic effect (FPG &lt;110 mg/dL, &lt;6.1 mmol/L) or to the highest dose level (up to glipizide 20 mg and FARXIGA 10 mg) as tolerated by patients. Thereafter, doses were kept constant, except for down-titration to prevent <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>At the end of the titration period, 87% of patients treated with FARXIGA had been titrated to the maximum study dose (10 mg) versus 73% treated with glipizide (20 mg). FARXIGA led to a similar mean reduction in HbA1c from baseline at Week 52 (LOCF), compared with glipizide, thus demonstrating noninferiority (see Table 12). FARXIGA treatment led to a statistically significant mean reduction in body weight from baseline at Week 52 (LOCF) compared with a mean increase in body weight in the glipizide group. Statistically significant (p&lt;0.0001) mean change from baseline in systolic blood pressure relative to glipizide plus metformin was âˆ’5.0Â mmHg with FARXIGA plus metformin.</p>
<a name="_RefID0EK5BI"></a><table width="100%">
<caption><span>Table 12: Results at Week 52 (LOCF*) in an Active-Controlled Study Comparing FARXIGA to Glipizide as Add-On to Metformin</span></caption>
<col width="65%">
<col width="18%">
<col width="18%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">FARXIGA</span><br><span class="Bold">+ Metformin</span><br><span class="Bold">N=400<span class="Sup">â€ </span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Glipizide</span><br><span class="Bold">+ Metformin</span><br><span class="Bold">N=401<span class="Sup">â€ </span></span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">*Â Â LOCF: last observation carried forward.<br><span class="Sup">â€ </span>Â Â Randomized and treated patients with baseline and at least 1 postbaseline efficacy measurement.<br><span class="Sup">â€¡</span>Â Â Least squares mean adjusted for baseline value.<br><span class="Sup">Â§</span>Â Â Noninferior to glipizide + metformin.<br><span class="Sup">Â¶</span>Â Â p-value &lt;0.0001.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from glipizide + metformin (adjusted mean<span class="Sup">â€¡</span>)<br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.0<span class="Sup">Â§</span><br>(âˆ’0.1, 0.1)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">88.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">87.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Â Â Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’3.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Â Â Difference from glipizide + metformin (adjusted mean<span class="Sup">â€¡</span>) <br>Â Â (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’4.7<span class="Sup">Â¶</span><br>(âˆ’5.1, âˆ’4.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_17dcbf4e-5a93-4862-b52e-4943bea84a3e"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Add-On Combination Therapy with Other Antidiabetic Agents</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_42e42ced-90bb-4eb3-8b6b-a648f3d73429"></a><a name="section-13.6.1"></a><p></p>
<h3><span class="Bold">Add-On Combination Therapy with a Sulfonylurea</span></h3>
<p class="First">A total of 597 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and inadequate glycemic control (HbA1c â‰¥7% and â‰¤10%) were randomized in this 24-week, placebo-controlled study to evaluate FARXIGA in combination with glimepiride (a sulfonylurea).</p>
<p>Patients on at least half the maximum recommended dose of glimepiride as monotherapy (4 mg) for at least 8 weeks lead-in were randomized to FARXIGA 5 mg, FARXIGA 10 mg, or placebo in addition to glimepiride 4 mg per day. Down-titration of glimepiride to 2 mg or 0 mg was allowed for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> during the treatment period; no up-titration of glimepiride was allowed.</p>
<p>In combination with glimepiride, FARXIGA 10 mg provided statistically significant improvement in HbA1c, FPG, and 2-hour PPG, and statistically significant reduction in body weight compared with placebo plus glimepiride at Week 24 (see Table 13). Statistically significant (p&lt;0.05 for both doses) mean changes from baseline in systolic blood pressure relative to placebo plus glimepiride were âˆ’2.8 mmHg and âˆ’3.8 mmHg with FARXIGA 5 mg and 10 mg plus glimepiride, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_82d88d87-bd84-4710-aeaa-fb6b016ab084"></a><a name="section-13.6.2"></a><p></p>
<h3><span class="Bold">Add-On Combination Therapy with a Thiazolidinedione</span></h3>
<p class="First">A total of 420 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with inadequate glycemic control (HbA1c â‰¥7% and â‰¤10.5%) participated in a 24-week, placebo-controlled study to evaluate FARXIGA in combination with pioglitazone (a thiazolidinedione [TZD]) alone. Patients on a stable dose of pioglitazone of 45 mg per day (or 30 mg per day, if 45 mg per day was not tolerated) for 12 weeks were randomized after a 2-week lead-in period to 5 or 10 mg of FARXIGA or placebo in addition to their current dose of pioglitazone. Dose titration of FARXIGA or pioglitazone was not permitted during the study.</p>
<p>In combination with pioglitazone, treatment with FARXIGA 10 mg provided statistically significant improvements in HbA1c, 2-hour PPG, FPG, the proportion of patients achieving HbA1c &lt;7%, and a statistically significant reduction in body weight compared with the placebo plus pioglitazone treatment groups (see Table 13) at Week 24. A statistically significant (p&lt;0.05) mean change from baseline in systolic blood pressure relative to placebo in combination with pioglitazone was âˆ’4.5Â mmHg with FARXIGA 10 mg in combination with pioglitazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0c9c4054-b322-4caa-9385-c2ad13e8480c"></a><a name="section-13.6.3"></a><p></p>
<h3><span class="Bold">Add-On Combination Therapy with a DPP4 Inhibitor</span></h3>
<p class="First">A total of 452 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who were drug naive, or who were treated at entry with metformin or a DPP4 inhibitor alone or in combination, and had inadequate glycemic control (HbA1c â‰¥7.0% and â‰¤10.0% at randomization), participated in a 24-week, placebo-controlled study to evaluate FARXIGA in combination with sitagliptin (a DPP4 inhibitor) with or without metformin.</p>
<p>Eligible patients were stratified based on the presence or absence of background metformin (â‰¥1500 mg per day), and within each stratum were randomized to either FARXIGA 10 mg plus sitagliptin 100 mg once daily, or placebo plus sitagliptin 100 mg once daily. Endpoints were tested for FARXIGA 10 mg versus placebo for the total study group (sitagliptin with and without metformin) and for each stratum (sitagliptin alone or sitagliptin with metformin). Thirty-seven percent (37%) of patients were drug naive, 32% were on metformin alone, 13% were on a DPP4 inhibitor alone, and 18% were on a DPP4 inhibitor plus metformin. Dose titration of FARXIGA, sitagliptin, or metformin was not permitted during the study.</p>
<p>In combination with sitagliptin (with or without metformin), FARXIGA 10 mg provided statistically significant improvements in HbA1c, FPG, and a statistically significant reduction in body weight compared with the placebo plus sitagliptin (with or without metformin) group at Week 24 (see Table 13). These improvements were also seen in the stratum of patients who received FARXIGA 10 mg plus sitagliptin alone (placebo-corrected mean change for HbA1c âˆ’0.56%; n=110) compared with placebo plus sitagliptin alone (n=111), and the stratum of patients who received FARXIGA 10 mg plus sitagliptin and metformin (placebo-corrected mean change for HbA1c âˆ’0.40; n=113) compared with placebo plus sitagliptin with metformin (n=113).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_93d85880-5e5e-442a-9d24-7abb19088bbd"></a><a name="section-13.6.4"></a><p></p>
<h3><span class="Bold">Add-On Combination Therapy with Insulin</span></h3>
<p class="First">A total of 808 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who had inadequate glycemic control (HbA1c â‰¥7.5% and â‰¤10.5%) were randomized in a 24-week, placebo-controlled study to evaluate FARXIGA as add-on therapy to insulin. Patients on a stable insulin regimen, with a mean dose of at least 30 IU of injectable insulin per day, for a period of at least 8Â weeks prior to enrollment and on a maximum of 2 oral antidiabetic medications (OADs), including metformin, were randomized after completing a 2-week enrollment period to receive either FARXIGA 5 mg, FARXIGA 10 mg, or placebo in addition to their current dose of insulin and other OADs, if applicable. Patients were stratified according to the presence or absence of background OADs. Up- or down-titration of insulin was only permitted during the treatment phase in patients who failed to meet specific glycemic goals. Dose modifications of blinded study medication or OAD(s) were not allowed during the treatment phase, with the exception of decreasing OAD(s) where there were concerns over <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> after cessation of insulin therapy.</p>
<p>In this study, 50% of patients were on insulin monotherapy at baseline, while 50% were on 1 or 2 OADs in addition to insulin. At Week 24, FARXIGA 10 mg dose provided statistically significant improvement in HbA1c and reduction in mean insulin dose, and a statistically significant reduction in body weight compared with placebo in combination with insulin, with or without up to 2 OADs (see Table 13); the effect of FARXIGA on HbA1c was similar in patients treated with insulin alone and patients treated with insulin plus OAD. Statistically significant (p&lt;0.05) mean change from baseline in systolic blood pressure relative to placebo in combination with insulin was âˆ’3.0 mmHg with FARXIGA 10 mg in combination with insulin.</p>
<p>At Week 24, FARXIGA 5 mg (âˆ’5.7 IU, difference from placebo) and 10 mg (âˆ’6.2 IU, difference from placebo) once daily resulted in a statistically significant reduction in mean daily insulin dose (p&lt;0.0001 for both doses) compared to placebo in combination with insulin, and a statistically significantly higher proportion of patients on FARXIGA 10 mg (19.6%) reduced their insulin dose by at least 10% compared to placebo (11.0%).</p>
<a name="_RefID0E4FCI"></a><table width="100%">
<caption><span>Table 13: Results of 24-Week (LOCF*) Placebo-Controlled Studies of FARXIGA in Combination with Antidiabetic Agents</span></caption>
<col width="57%">
<col width="18%">
<col width="17%">
<col width="9%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Efficacy Parameter</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">FARXIGA 10 mg</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">FARXIGA 5 mg</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â LOCF: last observation (prior to rescue for rescued patients) carried forward.<br><span class="Sup">â€ </span>Â Â Randomized and treated patients with baseline and at least 1 postbaseline efficacy measurement.<br><span class="Sup">â€¡</span>Â Â Least squares mean adjusted for baseline value.<br><span class="Sup">Â§</span>Â Â p-value &lt;0.0001 versus placebo.<br><span class="Sup">Â¶</span>Â Â 2-hour PPG level as a response to a 75-gram oral glucose tolerance test (OGTT).<br><span class="Sup">#</span>Â Â All randomized patients who took at least one dose of double-blind study medication during the short-term, double-blind period.<br>**Â Â p-value &lt;0.05 versus placebo. <br><span class="Sup">â€ â€ </span>Â Â  NT: Not formally tested because of failing to achieve a statistically significant difference in an endpoint that was earlier in the testing sequence.</td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">In Combination with Sulfonylurea (Glimepiride)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Intent-to-Treat Population</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=151<span class="Sup">â€ </span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=142<span class="Sup">â€ </span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=145<span class="Sup">â€ </span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo + glimepiride (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.7<span class="Sup">Â§</span><br>(âˆ’0.9, âˆ’0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5<span class="Sup">Â§</span><br>(âˆ’0.7, âˆ’0.3)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Percent of patients achieving HbA1c &lt;7% <br>adjusted for baseline</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31.7%<span class="Sup">Â§</span><br></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30.3%<span class="Sup">Â§</span><br></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13.0%<br></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">172.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">174.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">172.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’28.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’21.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo + glimepiride (adjusted mean<span class="Sup">â€¡</span>) (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’26.5<span class="Sup">Â§</span><br>(âˆ’33.5, âˆ’19.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’19.3<span class="Sup">Â§</span><br>(âˆ’26.3, âˆ’12.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">2-hour PPG</span><span class="Sup">Â¶</span><span class="Bold"> (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">329.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">322.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">324.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’60.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“54.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’11.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo + glimepiride (adjusted mean<span class="Sup">â€¡</span>) (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’49.1<span class="Sup">Â§</span><br>(âˆ’64.1, âˆ’34.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’43.0<span class="Sup">Â§</span><br>(â€“58.4, âˆ’27.5)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">81.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">80.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo + glimepiride (adjusted mean<span class="Sup">â€¡</span>) (95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.5<span class="Sup">Â§</span><br>(âˆ’2.2, âˆ’0.9)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.8<span class="Sup">Â§</span><br>(âˆ’1.5, âˆ’0.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="4"><p class="First"><span class="Bold">In Combination with Thiazolidinedione (Pioglitazone)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Intent-to-Treat Population</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=140</span><span class="Sup">#</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=141</span><span class="Sup">#</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=139</span><span class="Sup">#</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>)<br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.6<span class="Sup">Â§</span><br>(âˆ’0.8, âˆ’0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.4<span class="Sup">Â§</span><br>(âˆ’0.6, âˆ’0.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Percent of patients achieving HbA1c &lt;7% <br>adjusted for baseline</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">38.8%**</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32.5%**</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22.4%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">164.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">168.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">160.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’29.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’24.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’24.1<span class="Sup">Â§</span><br>(âˆ’32.2, âˆ’16.1)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’19.5<span class="Sup">Â§</span><br>(âˆ’27.5, âˆ’11.4)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">2-hour PPG</span><span class="Sup">Â¶</span><span class="Bold"> (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">308.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">284.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">293.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’67.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’65.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’14.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’53.3<span class="Sup">Â§</span><br>(âˆ’71.1, âˆ’35.6)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’51.0<span class="Sup">Â§</span><br>(âˆ’68.7, âˆ’33.2)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">84.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">87.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">86.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.8<span class="Sup">Â§</span><br>(âˆ’2.6, âˆ’1.0)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.6<span class="Sup">Â§</span><br>(âˆ’2.3, âˆ’0.8)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="4"><p class="First"><span class="Bold">In Combination with DPP4 Inhibitor (Sitagliptin) with or without Metformin</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Intent-to-Treat Population</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=223<span class="Sup">â€ </span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">â€“</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=224<span class="Sup">â€ </span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.90</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7.97</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.45</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.04</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.48<span class="Sup">Â§</span><br>(âˆ’0.62, âˆ’0.34)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Patients with HbA1c decrease â‰¥0.7% (adjusted percent)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35.4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16.6%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">161.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">163.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline at Week 24 (adjusted mean<span class="Sup">â€¡</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’24.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’27.9<span class="Sup">Â§</span><br>(âˆ’34.5, âˆ’21.4)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">91.02</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">89.23</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’2.14</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.26</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>)<br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.89<span class="Sup">Â§</span><br>(âˆ’2.37, âˆ’1.40)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="4"><p class="First"><span class="Bold">In Combination with Insulin with or without up to 2 Oral Antidiabetic Therapies</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Intent-to-Treat Population</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=194<span class="Sup">â€ </span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=211<span class="Sup">â€ </span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=193<span class="Sup">â€ </span></span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">HbA1c (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.9</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.8</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>)<br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.6<span class="Sup">Â§</span><br>(âˆ’0.7, âˆ’0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’0.5<span class="Sup">Â§</span><br>(âˆ’0.7, âˆ’0.4)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">173.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NT<span class="Sup">â€ â€ </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">170.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’21.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NT<span class="Sup">â€ â€ </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>)<br>(95% CI) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’25.0<span class="Sup">Â§</span><br>(âˆ’34.3, âˆ’15.8)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NT<span class="Sup">â€ â€ </span></p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4"><p class="First"><span class="Bold">Body Weight (kg)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Baseline (mean) </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">94.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">93.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">94.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Change from baseline (adjusted mean<span class="Sup">â€¡</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Difference from placebo (adjusted mean<span class="Sup">â€¡</span>) <br>(95% CI)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.7<span class="Sup">Â§</span><br>(âˆ’2.2, âˆ’1.2)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">âˆ’1.0<span class="Sup">Â§</span><br>(âˆ’1.5, âˆ’0.5)</p></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_03b9ef1c-1e30-4ac8-9d70-4596853aa4db"></a><a name="section-13.7"></a><p></p>
<h2>14.7 Use in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The efficacy of FARXIGA was assessed in a study of diabetic patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (252 patients with mean eGFR 45 mL/min/1.73 m<span class="Sup">2</span>). FARXIGA did not show efficacy in this study. The placebo-corrected mean HbA1c change at 24Â weeks was âˆ’0.1% (95% CI [âˆ’0.4%, 0.2%]) for both FARXIGA 5 mg (n=83) and 10 mg (n=82).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_47ed3557-262d-4358-a3e2-5bd5461c1513"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1f560f02-ff98-41c9-ad6d-ec91821487fa"></a><a name="section-14.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef44c617-f129-4581-8cf6-156a09fe5151"></a><a name="section-14.1.1"></a><p></p>
<h3><span class="Bold">How Supplied</span></h3>
<p class="First">FARXIGA (dapagliflozin) tablets have markings on both sides and are available in the strengths and packages listed in Table 14.</p>
<a name="_RefID0EEODI"></a><table width="100%">
<caption><span>Table 14: FARXIGA Tablet Presentations</span></caption>
<col width="13%">
<col width="16%">
<col width="38%">
<col width="22%">
<col width="11%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet Strength</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Film-Coated Tablet</span><br><span class="Bold">Color/Shape</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Tablet</span><br><span class="Bold">Markings</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Package Size</span></th>
<th class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">NDC Code</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">5 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">yellow, <br>biconvex, <br>round</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">â€œ5â€? engraved on one <br>side and â€œ1427â€? engraved on the other side</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Bottles of 30 <br>Bottles of 90 <br>Bottles of 500 <br>Hospital Unit Dose Cartons of 100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0003-1427-11 <br>0003-1427-12 <br>0003-1427-13 <br>0003-1427-14</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">10 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">yellow, <br>biconvex, <br>diamond-shaped</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">â€œ10â€? engraved on one side and â€œ1428â€? engraved on the other side</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Bottles of 30 <br>Bottles of 90 <br>Bottles of 500 <br>Hospital Unit Dose Cartons of 100</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0003-1428-11 <br>0003-1428-12 <br>0003-1428-13 <br>0003-1428-14</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_87dcc166-94b8-405e-a55b-f4b0a16ba1cf"></a><a name="section-14.1.2"></a><p></p>
<h3><span class="Bold">Storage and Handling</span></h3>
<p class="First">Store at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_41e47a06-53e3-4414-9d7d-6afc2177b899"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bc7c2b91-eb7a-4cf7-a621-9c0bd93cc108"></a><a name="section-15.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f3a2e5de-8642-47ce-acff-f5dd72a357ef"></a><a name="section-15.1.1"></a><p></p>
<h3><span class="Bold">Instructions</span></h3>
<p class="First">Instruct patients to read the Medication Guide before starting treatment with FARXIGA and to reread it each time the prescription is renewed.</p>
<p>Inform patients of the potential risks and benefits of FARXIGA and of alternative modes of therapy. Also inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1c testing, recognition and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and assessment of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> complications. Advise patients to seek medical advice promptly during periods of stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, as medication requirements may change.</p>
<p>Instruct patients to take FARXIGA only as prescribed. If a dose is missed, advise patients to take it as soon as it is remembered unless it is almost time for the next dose, in which case patients should skip the missed dose and take the medicine at the next regularly scheduled time. Advise patients not to take two doses of FARXIGA at the same time.</p>
<p>Inform patients that the most common adverse reactions associated with use of FARXIGA are genital mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
<p>Instruct patient to immediately inform her healthcare provider if she is pregnant or plans to become pregnant. Based on animal data, FARXIGA may cause fetal harm in the second and third trimesters of pregnancy.</p>
<p>Instruct patient to immediately inform her healthcare provider if she is breastfeeding or planning to breastfeed. It is not known if FARXIGA is excreted in breast milk; however, based on animal data, FARXIGA may cause harm to nursing infants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_11f01f07-eaec-4209-b999-71449ade5e38"></a><a name="section-15.1.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></h3>
<p class="First">Inform patients that symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur with FARXIGA and advise them to contact their healthcare provider if they experience such symptoms [see <span class="Italics"><a href="#ID_8cb7c5eb-a657-4079-b403-83d52999887d">Warnings and PrecautionsÂ (5.1)</a></span>]. Inform patients that <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may increase the risk for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and to have adequate fluid intake.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_140906ee-4eb2-4380-be6c-5956ae4497dc"></a><a name="section-15.1.3"></a><p></p>
<h3><span class="Bold">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Females (e.g., <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span>)</span></h3>
<p class="First">Inform female patients that vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> may occur and provide them with information on the signs and symptoms of vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>. Advise them of treatment options and when to seek medical advice [see <span class="Italics"><a href="#ID_3745c009-b8d6-43ba-abf7-7dadfec65295">Warnings and PrecautionsÂ (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_906cc9a8-95ed-420d-b629-92c618fe260b"></a><a name="section-15.1.4"></a><p></p>
<h3><span class="Bold">Genital Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Males (e.g., <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">Balanitis</span>)</span></h3>
<p class="First">Inform male patients that <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> of the penis (e.g.,Â <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> or <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>) may occur, especially in patients with prior history. Provide them with information on the signs and symptoms of <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span> and <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span> (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the glans or foreskin of the penis). Advise them of treatment options and when to seek medical advice [see <span class="Italics"><a href="#ID_3745c009-b8d6-43ba-abf7-7dadfec65295">Warnings and PrecautionsÂ (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0fe39fcd-9289-4e84-9bb1-751b1f26bb9c"></a><a name="section-15.1.5"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></h3>
<p class="First">Inform patients that serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) have been reported with FARXIGA. Advise patients to immediately report any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and to take no more of the drug until they have consulted prescribing physicians.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5c21407-9cd4-4e54-b30e-7378ba36d9c3"></a><a name="section-15.1.6"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span></h3>
<p class="First">Inform patients of the potential for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Provide them with information on the symptoms of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Advise them to seek medical advice if such symptoms occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0bcbcb09-08b5-4a9b-9559-f1c4b421bf98"></a><a name="section-15.1.7"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder Cancer</span></span></h3>
<p class="First">Inform patients to promptly report any signs of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">macroscopic hematuria</span> or other symptoms potentially related to <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_35a23fb9-68ea-470d-82d8-e9a1d35bdd5b"></a><a name="section-15.1.8"></a><p></p>
<h3><span class="Bold">Laboratory Tests</span></h3>
<p class="First">Due to its mechanism of action, patients taking FARXIGA will test positive for glucose in their urine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_84858349-0164-4b08-bad5-378430e41c23"></a><a name="section-16"></a><p></p>
<p class="First"><br><br>Manufactured by:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA</p>
<p><br>Marketed by:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543<br>and<br>AstraZeneca Pharmaceuticals LP<br>Wilmington, DE 19850</p>
<p><br>Product of Ireland</p>
<p><br>Revised: August 2014</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_c9cf1f81-1eb5-41fe-aef1-b86154f1a20f"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE<br>FARXIGA (far-SEE-guh)<br>(dapagliflozin)<br>tablets</h1>
<p class="First"><span class="Bold">What is the most important information I should know about FARXIGA?</span></p>
<p><span class="Bold">FARXIGA can cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>.</span> FARXIGA can cause some people to have <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> (the loss of body water and salt). <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span> may cause you to feel dizzy, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lightheaded, or weak, especially when you stand up (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>). You may be at a higher risk of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> if you:<dl>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></dd>
<dt>â€¢</dt>
<dd>take medicines to lower your blood pressure, including water pills (diuretics)</dd>
<dt>â€¢</dt>
<dd>are 65 years of age or older</dd>
<dt>â€¢</dt>
<dd>are on a low salt diet</dd>
<dt>â€¢</dt>
<dd>have kidney problems</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span>.</span> Women who take FARXIGA may get vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span>. Symptoms of a vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> include:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4162573" conceptname="Vaginal odor">vaginal odor</span></dd>
<dt>â€¢</dt>
<dd>white or yellowish <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> (discharge may be lumpy or look like cottage cheese)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4194652" conceptname="Pruritus of vulva">vaginal itching</span></dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Yeast infection</span> of the penis (<span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanitis</span>).</span> Men who take FARXIGA may get a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the skin around the penis. Certain men who are not circumcised may have <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the penis that makes it difficult to pull back the skin around the tip of the penis. Other symptoms of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the penis include:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the penis</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of the penis</dd>
<dt>â€¢</dt>
<dd>foul smelling discharge from the penis</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the skin around the penis</dd>
</dl>
</dd>
</dl>
<p>Talk to your healthcare provider about what to do if you get symptoms of a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span> of the vagina or penis. Your healthcare provider may suggest you use an over-the-counter antifungal medicine. Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder cancer</span>.</span> In studies of FARXIGA in people with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> occurred in a few more people who were taking FARXIGA than in people who were taking other <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medications. There were too few cases to know if <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> was related to FARXIGA. You should not take FARXIGA if you have <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Tell your healthcare provider right away if you have any of the following symptoms:<dl>
<dt>â€¢</dt>
<dd>blood or a red color in your urine</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> while you urinate</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What is FARXIGA?</span></p>
<p>FARXIGA is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>FARXIGA is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<p>FARXIGA is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in your blood or urine).</p>
<p>It is not known if FARXIGA is safe and effective in children younger than 18 years of age.</p>
<p><span class="Bold">Who should not take FARXIGA?</span></p>
<p><span class="Bold">Do not take FARXIGA if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to dapagliflozin or any of the ingredients in FARXIGA. See the end of this Medication Guide for a list of ingredients in FARXIGA. Symptoms of a <span class="Bold">serious</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to FARXIGA may include:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></dd>
<dt>â€¢</dt>
<dd>raised red patches on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing</dd>
</dl>
</dd>
<dt>Â </dt>
<dd>If you have any of these symptoms, stop taking FARXIGA and contact your healthcare provider or go to the nearest hospital emergency room right away.</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>have severe kidney problems or are on dialysis.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking FARXIGA?</span></p>
<p><span class="Bold">Before you take FARXIGA, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or have had <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>.</dd>
<dt>â€¢</dt>
<dd>have kidney problems.</dd>
<dt>â€¢</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. FARXIGA may harm your unborn baby. If you are pregnant or plan to become pregnant, talk to your healthcare provider about the best way to control your blood sugar. </dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if FARXIGA passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby if you are taking FARXIGA.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How should I take FARXIGA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take FARXIGA exactly as your healthcare provider tells you to take it.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not</span> change your dose of FARXIGA without talking to your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>Take FARXIGA by mouth 1 time each day, with or without food.</dd>
<dt>â€¢</dt>
<dd>When your body is under some types of stress, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> (such as a car <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, the amount of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine you need may change. Tell your healthcare provider right away if you have any of these conditions and follow your healthcare providerâ€™s instructions.</dd>
<dt>â€¢</dt>
<dd>Stay on your prescribed diet and exercise program while taking FARXIGA.  </dd>
<dt>â€¢</dt>
<dd>Your healthcare provider may do certain blood tests before you start FARXIGA and during your treatment.  </dd>
<dt>â€¢</dt>
<dd>Your healthcare provider will check your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with regular blood tests, including your blood sugar levels and your A1c.</dd>
<dt>â€¢</dt>
<dd>Follow your healthcare providerâ€™s instructions for treating low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). Talk to your healthcare provider if low blood sugar is a problem for you.</dd>
<dt>â€¢</dt>
<dd>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. <span class="Bold">Do not</span> take 2 doses of FARXIGA at the same time.</dd>
<dt>â€¢</dt>
<dd>If you take too much FARXIGA, call your healthcare provider or go to the nearest emergency room right away.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of FARXIGA?</span></p>
<p><span class="Bold">FARXIGA may cause serious side effects, including:</span></p>
<p>See â€œ<span class="Bold">What is the most important information I should know about FARXIGA?</span>â€?</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span> If you take FARXIGA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take FARXIGA. Signs and symptoms of low blood sugar may include: <dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></dd>
<dt>â€¢</dt>
<dd>fast heartbeat</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Kidney problems</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Increased fats in your blood (bad <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or LDL)</span></dd>
</dl>
<p><span class="Bold">The most common side effects of FARXIGA include:</span></p>
<dl>
<dt>â€¢</dt>
<dd>vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> of the penis </dd>
<dt>â€¢</dt>
<dd>stuffy or <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span></dd>
<dt>â€¢</dt>
<dd>changes in urination, including urgent need to urinate more often, in larger amounts, or at night</dd>
</dl>
<p>These are not all the possible side effects of FARXIGA. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store FARXIGA?</span></p>
<p>Store FARXIGA at room temperature between 68Â°F and 77Â°F (20Â°C and 25Â°C). </p>
<p><span class="Bold">General information about the safe and effective use of FARXIGA</span></p>
<p>This Medication Guide summarizes the most important information about FARXIGA. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about FARXIGA that is written for healthcare professionals.</p>
<p>For more information about FARXIGA, go to www.farxiga.com or call 1-800-321-1335.</p>
<p><span class="Bold">What are the ingredients in FARXIGA?</span></p>
<p><span class="Bold">Active ingredient:</span> dapagliflozin.</p>
<p><span class="Bold">Inactive ingredients: </span>microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. The film coating contains: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.</p>
<p><br><br><br>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><br>Manufactured by:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA</p>
<p><br>Marketed by:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543<br>and<br>AstraZeneca Pharmaceuticals LP<br>Wilmington, DE 19850</p>
<p><br>Product of Ireland</p>
<p><br>Revised: August 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f3baa2da-12f5-4b10-8eb6-8b72b0568e68"></a><a name="section-18"></a><p></p>
<h1>FARXIGA 5 mg tablets Representative Packaging</h1>
<p class="First">See <span class="Bold">How Supplied</span> section for a complete list of available packages of FARXIGA.</p>
<p><span class="Bold">30 Tablets</span><br><span class="Bold">NDC 0003-1427-11</span><br><span class="Bold">farxiga</span><br><span class="Bold">(dapagliflozin) tablets</span><br><span class="Bold">5 mg</span><br><span class="Bold">Dispense with Medication Guide</span><br><span class="Bold">Rx only</span><br>Bristol-Myers SquibbÂ Â Â Â Â AstraZeneca</p>
<div class="Figure">
<a name="id50816896"></a><img alt="FARXIGA 5 mg 30s Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998&amp;name=farxiga-5mg-30s.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_68af8ecb-3d43-47b3-995c-aa51b03ed6e6"></a><a name="section-19"></a><p></p>
<h1>FARXIGA 10 mg tablets Representative Packaging</h1>
<p class="First"><span class="Bold">30 Tablets</span><br><span class="Bold">NDC 0003-1428-11</span><br><span class="Bold">farxiga</span><br><span class="Bold">(dapagliflozin) tablets</span><br><span class="Bold">10 mg</span><br><span class="Bold">Dispense with Medication Guide</span><br><span class="Bold">Rx only</span><br>Bristol-Myers SquibbÂ Â Â Â Â AstraZeneca</p>
<div class="Figure">
<a name="id71016673"></a><img alt="FARXIGA 10 mg 30s Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fc6ae30e-868b-4ac9-b69d-900922503998&amp;name=farxiga-10mg-30s.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FARXIGAÂ 		
					</strong><br><span class="contentTableReg">dapagliflozin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-1427</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DAPAGLIFLOZIN PROPANEDIOL</strong> (dapagliflozin) </td>
<td class="formItem">dapagliflozin</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">5;1427</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-1427-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">01/08/2014</td>
<td class="formItem">04/30/2017</td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0003-1427-12</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0003-1427-13</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0003-1427-14</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0003-1427-91</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem">01/08/2014</td>
<td class="formItem">05/16/2016</td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202293</td>
<td class="formItem">01/08/2014</td>
<td class="formItem">04/30/2017</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FARXIGAÂ 		
					</strong><br><span class="contentTableReg">dapagliflozin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0003-1428</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DAPAGLIFLOZIN PROPANEDIOL</strong> (dapagliflozin) </td>
<td class="formItem">dapagliflozin</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">DIAMOND (biconvenx) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10;1428</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0003-1428-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem">01/08/2014</td>
<td class="formItem">08/31/2017</td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0003-1428-12</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0003-1428-13</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0003-1428-14</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:0003-1428-91</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem">01/08/2014</td>
<td class="formItem">10/31/2016</td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202293</td>
<td class="formItem">01/08/2014</td>
<td class="formItem">08/31/2017</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>E.R. Squibb &amp; Sons, L.L.C.
							(011550092)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1bc7cf83-520d-41e0-8255-5fcd83bfdfc7</div>
<div>Set id: fc6ae30e-868b-4ac9-b69d-900922503998</div>
<div>Version: 3</div>
<div>Effective Time: 20140811</div>
</div>
</div>Â <div class="DistributorName">E.R. Squibb &amp; Sons, L.L.C.</div></p>
</body></html>
